MATERIALS AND METHODS

Similar documents
GUIDELINES ON ERECTILE DYSFUNCTION

GUIDELINES ON ERECTILE DYSFUNCTION

Tadalafil Rehabilitation Therapy Preserves Penile Size After Bilateral Nerve Sparing Radical Retropubic Prostatectomy

Managing the Patient with Erectile Dysfunction: What Would You Do?

IC351 (tadalafil, Cialis): update on clinical experience

Erectile Dysfunction: A Primer for Primary Care Providers

, David Stultz, MD. Erectile Dysfunction. David Stultz, MD September 10, 2001

Assessment of Erectile and Ejaculatory Function after Penile Prosthesis Implantation

Sexual Dysfunction. Jae Il Kang, Byeong Kuk Ham, Mi Mi Oh, Je Jong Kim, Du Geon Moon. DOI: /kju

A Proposed Study of Hyperbaric Oxygen Therapy Following Radical Prostatectomy: Effects on Erectile Dysfunction

Review Article Penile Rehabilitation Therapy with PDE-V Inhibitors Following Radical Prostatectomy: Proceed with Caution

1. Introduction. emerged as an important indicator of men s overall health, due to the very closed relationship to concomitant comorbidities

Erectile dysfunction. By Anas Hindawi Supervised by Dr Khalid AL Sayyid

/02/ /0 Vol. 168, , October 2002 THE JOURNAL OF UROLOGY

Testosterone and PDE5 inhibitors in the aging male

/04/ /0 Reprinted from Vol. 172, , August 2004 THE JOURNAL OF UROLOGY

Daily vs. on-demand PDE-5 inhibitors for management of erectile dysfunction following treatment for prostate cancer

Efficacy and Safety of Linear Focused Shockwaves for Erectile Dysfunction (RENOVA) A Second Generation Technology

/03/ /0 Vol. 170, , July 2003 THE JOURNAL OF UROLOGY. Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION

Erectile Dysfunction and the Prostate Cancer Patient

Sidney Glina Faculdade de Medicina do ABC Instituto H. Ellis Editor-in-Chief of the International Brazilian Journal of Urology

Disclosure Slide. Dr Michael Gillman IMPOTENCE ERECTILE DIFFICULTIES. Do Men Really Care??? 15/10/2014 ASSESSMENT OF ERECTILE DYSFUNCTION

Managing Erectile Dysfunction

LSWT. Linear Shockwave Therapy for Erectile Dysfunction Clinical Data and Reports

Clinical evaluation of Tentex forte and Himcolin cream in the treatment of functional erectile dysfunction

Experimental Model of Human Corpus Cavernosum Smooth Muscle Relaxation

ERECTILE DYSFUNCTION DIAGNOSIS

ERECTILE DYSFUNCTION. Prof. Khan Abul Kalam Azad. Head, Department of Medicine, Dhaka Medical College President, Bangladesh Society of Medicine

Dipartimento Ostetricia, Ginecologia, Urologia - Clinica Urologica Università di Napoli Federico II, Italy; 2

LSWT. Linear Shockwave Therapy for Erectile Dysfunction Clinical Data and Reports

Onset and duration of action of sildena l citrate for the treatment of erectile dysfunction

MALE SEXUAL DYSFUNCTION. Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara

Shockwave Therapy Applications

Erectile dysfunction: unmet needs

TITLE: Phosphodiesterase 5 Inhibitors: A Review of the Clinical Effectiveness and Cost- Effectiveness

Different hemodynamic responses by color Doppler ultrasonography studies between sildenafil non-responders and responders

Erectile Dysfunction Medical Treatment

Canadian Undergraduate Urology Curriculum (CanUUC): Erectile Dysfunction

The Role of Testosterone in the Sexual Function. Luiz Otavio Torres President Elect of ISSM Belo Horizonte - Brazil

GUIDELINES ON MALE SEXUAL DYSFUNCTION: Erectile Dysfunction and Premature Ejaculation

LONG-TERM EFFECT OF SILDENAFIL CITRATE ON ERECTILE DYSFUNCTION AFTER RADICAL PROSTATECTOMY: 3-YEAR FOLLOW-UP

Product Introduction

Is there a role for extracorporeal shock wave therapy for erectile dysfunction unresponsive to phosphodiesterase type 5 inhibitors?

Defined as the consistent inability to attain and maintain an erection adequate for sexual intercourse Usually qualified by being present for several

ERECTION MISDIRECTION: PENILE REHABILITATION & TREATMENTS FOR ERECTILE DYSFUNCTION. Gregory Harochaw Pharmacy Manager Tache Pharmacy (204)

SEXUAL HEALTH. Erectile Dysfunction

Sexual dysfunction in men with diabetes

Erectile Dysfunction Case Study 2. Medical Student Case-Based Learning

ORIGINAL ARTICLE Post-marketing surveillance study of the efficacy and safety of vardenafil among patients with erectile dysfunction in primary care

Sponsored by. Schering. Sidney Glina

I N T I M A C Y A N D S E X U A L I T Y I N L A T E R L I F E

Smooth muscle pathology and erectile dysfunction

Medicines Q&As. Date prepared: November 2016

The New England Journal of Medicine

13-Oct-15 ERECTILE DYSFUNCTION. Urology Subdepartement dr. Mintohardjo Naval Hospital dr. Isdiyanto Septiadi, Sp.U

MANAGEMENT UPDATE , LLC MedReviews

Corporate Medical Policy

Initial experience with linear focused shockwave treatment for erectile dysfunction: a 6-month follow-up pilot study

Evidence Review for Surrey Prescribing Clinical Network. Treatment: Oral and non-oral combination therapy for erectile dysfunction

ORIGINAL INVESTIGATION. Sildenafil for Male Erectile Dysfunction

Ecklonia Cava Research

LONG-TERM POTENCY AFTER IODINE-125 RADIOTHERAPY FOR PROSTATE CANCER AND ROLE OF SILDENAFIL CITRATE

Opinion: Yes. PDE-5 inhibitors should be used post radical prostatectomy as erection function rehabilitation?

Guidelines on Erectile Dysfunction

Chronic Daily Administration of Vardenafil in Erectile Dysfunction Patients Has No Impact on Semen Parameters or on Sex Hormones Levels

Preserved Postoperative Penile Size Correlates Well with Maintained Erectile Function after Bilateral Nerve-Sparing Radical Retropubic Prostatectomy

Erectile dysfunction (ED) is a common male sexual. Clinical Guidelines

Jan Farrell. Nurse Consultant Urology Department of Urology Rotherham General Hospital NHS FT

Review Article Overview of Contemporary Penile Rehabilitation Therapies

MMM. Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS

avanafil 50mg, 100mg, 200mg tablets (Spedra ) SMC No. (980/14) A. Menarini Farmaceutica Internazionale SRL.

SYED TABREZ ALI Department of Physiology, Faculty of Medicine P.O. Box 7607, Umm-Al-Qura University, Makkah, Saudi Arabia

Low Energy Shockwaves for the Treatment of Erectile Dysfunction Y. Vardi, B. Appel, I Gruenwald

Progression of Peyronie s Disease during Tamoxifen Treatment

Phosphodiesterase Type 5 Inhibitors Quantity Limit Program Summary

Diagnosis and management of sexual dysfunction. Dr Chris Simpson Consultant Psychiatrist

Sildenafil Citrate (VIAGRA ) Improves Erectile Function in Elderly Patients With Erectile Dysfunction: A Subgroup Analysis

Spring balance evaluation of the ischiocavernosus muscle

Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction

Cardiovascular Parameter Changes in Patients With Erectile Dysfunction Using Pde-5 Inhibitors: A Study With Sildenafil and Vardenafil

Male Sexual Dysfunction:

Erectile dysfunction (ED) is the inability to obtain or maintain an erection satisfactory

Management of Post-Prostatectomy Urinary Incontinence and Sexual Dysfunction

Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil

The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction

ERECTILE DYSFUNCTION TREATMENTS

Are Statins an Effective Treatment in Men With Erectile Dysfunction?

ERECTILE DYSFUNCTION IN CHINESE MEDICINE 马万里. Giovanni Maciocia

Sexual function and dysfunction in men

Up-titration of vardenafil dose from 10 mg to 20 mg improved erectile function in men with spinal cord injury

High dose sildenafil citrate as a salvage therapy for severe erectile dysfunction

Jan Farrell Nurse Consultant Urological Services Department of Urology Rotherham General Hospital NHS FT

The efficacy and safety of tadalafil: an update

for ED and LUTS/BPH Pierre Sarkis, M.D. Assistant Professor Fellow of the European Board of Urology

ERECTILE DYSFUNCTION. & Current Therapies. GP Conference, Rotorua 7-10 June 2012

Tadalafil: a novel treatment for erectile dysfunction

THE RELEVANCE OF TESTOSTERONE THERAPY IN MANAGING PATIENTS WITH ERECTILE DYSFUNCTION

Long-term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis

With My Heart, Can or Should I Take Erectile Dysfunction Drugs?

Erectile dysfunction (ED) is defined as the inability

Transcription:

ANALYZING THE EFFICACY OF A NEW NATURAL COMPOUND MADE OF ALGA ECKLONIA BICYCLIS, TRIBULUS TERRESTRIS AND BIOVIS IN ORDER TO IMPROVE MALE SEXUAL FUNCTION F. Iacono, D. Prezioso, A. Ruffo, G. Di Lauro*, L. Romis*, E. Illiano Chair of Urology. School of Medicine and Surgery. University Federico II. Naples. Italy. *Hospital Santa Maria delle Grazie, Pozzuoli, Naples, Italy. ABSTRACT PURPOSE: We investigated the therapeutical efficacy of the new natural drug composition based on Tribulus Terrestris, Biovis and Alga Ecklonia Bicyclis in order to improve male sexual function, selecting patients with the International Index of Erectile Function (IIEF), with the Nocturnal Penile Tumescence and Rigidity Testing (NPTR) with RigiScan device and hormonal levels. MATERIALS AND METHODS: 164 patients (pts) with erectile dysfunction (ED), 64 pts with mild ED, 62 pts with moderate ED and 38 pts with severe ED, were enrolled, from September 2009 to January 2010, mean age was 53.1 years. A new compound (150 mg of Alga Ecklonia Bicyclis, 396 mg of Tribulus Terrestris and 144 mg of Biovis) was administered to all the pts twice a day for 60 days. IIEF questionnaire (pre and post treatment) were carried out on all the pts and also Nocturnal Penile Tumescence and Rigidity Testing (NPTR) by Rigiscan device (pre and post treatment) were performed. RESULTS: On 150 evaluable pts, the IIEF scores were significantly improved in all the pts with an increase of 78% in mild ED group while in the moderate ED group there was an improvement of 80% and in the severe ED group of 108% from the baseline. The mean IIEF scores of all the patients showed significant improvement after 8 weeks of this new drug composition treatment (baseline 14.3 +/- 1.5 to 26.2 +/- 3.2 p = 0.01). Among other parameters penile rigidity and tumescence tested by RigiScan showed significant improvement for treated pts. Furthermore, no significant side effect were claimed.

CONCLUSIONS: The combination of the active principles of these three natural compounds : protodioscin, steroidal saponin, contained in Tribulus Terrestris, polyphenols, Dieckol, Florofucofuroeckol e Bieckol, contained in Alga Ecklonia Bicyclis and the polymers of d-glucosamine and n-acetyl-d-glucosamine contained in Biovis seems to work in synergy not just improving the erectile function but stimulating the T dependent sexual desire too. Protodioscin is able to stimulate the testosterone production and also it has got an androgen-mimetic action binding and activating the testosterone receptors. Polyphenols play an antinflammatory action, modulating the cytokines (lipopolisaccarids, TNF-alpha, IFN-gamma) with a potent antioxidant and antifibrotic effect. Biovis acts both on non-adrenergic and non-colinergic system (NANC) and on the endothelial cell system as an strong nitric oxide synthetase (NOS). Our study demonstrated that this new composition drug was effective in the oral treatment of ED. KEY WORDS Erectile Dysfunction, Biovis, Tribulus Terrestris, Alga Ecklonia Bicyclis, Phytotherapy, Phytomedicine, Natural Drugs, Antioxidant, Antifibrotic, Anti-aging, Nutraceutical INTRODUCTION The pharmacological treatment for the ED has reached a major importance among the therapeutic approaches to impotence. This example of successful therapy largely depended on advances in clinical and basic research, focused on local mechanisms of penile erection. The introduction of oral phosphodiesterase-5 inhibitors (PDE5-i) in the late 1990s and early 2000s revolutionized the field of sexual medicine having the great worth of arising the problem of the male ED allowing an effective treatment of this disease. In fact PDE5-i have become the most popular treatment and are currently first-line monotherapy for erectile dysfunction (ED) indicating that most of the patients prefer oral therapy [1]. However, a significant proportion of patients with complex ED will be therapeutic non-responders to PDE5-i monotherapy [2]. Furthermore these drugs present various problems for the wide spectrum of co-morbidities in patients with erectile dysfunction [3] in particular the daily use of anti-hypertensive drugs in patients with cardiovascular diseases can lead to dangerous side-effects [4].

Besides frequent reported side-effects such as headache, muscular pains, hot flushes, tearing and so on, can affect a normal sexual intercourse [3]. However, approximately 30% of patients are unresponsive to on-demand PDE5-i regimens due to both psychogenic and organic factors [5]. Psychological impact artificial erections and sexual intercourse planning -and a not proven yet curative effect, after the initial enthusiasms, has limited this drug use leaving an open field to further developments of more natural drugs to improve male sexual function. The new natural drug is based on a new composition of Tribulus Terrestris, Biovis and Alga Ecklonia Bicyclis, used in many countries with different dosages and associations to stimulate sexual function, although only few studies have been carried out on their efficacy [6]. The combination of the active principles present in these three natural compounds work in synergy and have shown, in our preliminary data [7], a good efficacy for the ED oral therapy. In this study we determined that the new natural compound based on Alga Ecklonia Bicyclis, Tribulus Terrestris and Biovis at elevate dosage is truly beneficial in improving male sexual function, according to currently available parameters, including the international index of erectile function (IIEF), hormonal levels, Nocturnal Penile Tumescence and Rigidometry tested by Rigiscan. MATERIALS AND METHODS Between September 2009 and January 2010, 164 pts with erectile dysfunction without previous treatment for the ED were enrolled for study inclusion. Exclusion criteria were an history of radical prostatectomy or spinal cord injury, serious neurological deficits such as multiple sclerosis and Parkinson s disease, genital abnormality, alcohol or drugs abuse, an history of hormonal therapy, androgen ablation or cancer chemotherapy, previous use of nitrate drugs and a severe vasculogenic impotence. Patients with concomitant medical diseases were included in our study if they had stable disease with concurrent medical therapy for cardiovascular disease, diabetes and so forth. All the patients at baseline were evaluated with medical and psychosexual history to detect co-morbidities. Organic co-morbidities included hypertension in 46 pts (28.1%), diabetes in 24 pts (14.6%) and abnormal total serum cholesterol in 14 pts (8.5%). Furthermore the IIEF Questionnaire was administered to each patient and the serum level of baseline testosterone was checked.

All the patients, after IIEF questionnaire, were divided into three groups: 1) group A, 64 pts (36,6%) affected by mild ED (IIEF score over 16); 2) group B, 62 pts (35,4%) affected by moderate ED (IIEF score between 11 and 16); 3) group C, 38 pts (19,5%) affected by severe ED (IIEF score below 10) [8] For each group we reported : erectile function (AREA 1), orgasmic function (AREA 2), sexual desire (AREA 3), intercourse satisfaction (AREA 4), overall satisfaction (AREA 5). (TABLE 1) Moreover all the patients were examined by penile dinamic Doppler ultrasonography and tested with NPRT using the Rigiscan device (UroHealth Systems, Laguna Niguel, California), to determine related baseline parameters, including rigidity, number and duration of the nocturnal penile erections [9]. After baseline evaluation, all the patients were treated for 8 weeks with this new natural drug composition (150 mg of Alga Ecklonia Bicyclis, 396 mg of Tribulus Terrestris and 144 mg of Biovis for each tablet) twice a day. IIEF was administered, testosterone levels were valued and NPTR was measured after the period of treatment. We used the Mann-Whitney test to determine the statistical significance of responses to global efficacy question, with the paired Student t test with significance considered at p < 0.01.

RESULTS During the treatment we had 14 drop-outs: 4 pts (2.4%) quit the therapy for mild gastrointestinal side effects (stomachache 3 pts, diarrhea 1 pt); 6 pts (3.6%) for low compliance, 2 pt (2.4%) for insomnia and 2 pt for personal concerns. At the end of the treatment we had 150 evaluable patients. The mean age of the patients was 53.1+/- 8.2 years. In the Table 1 we report the improvement in the IIEF after the 60 days of treatment in the three groups of the 150 evaluable patients. Group A showed an improvement in all domains of IIEF questionnaire scores, with a significant improvement after 8 weeks of treatment (from baseline 22.1 +/- 1.6 to 39.3 +/- 5.1 p = 0.00000). Also Group B showed an improvement in all domains of IIEF questionnaire, with a significant improvement after 8 weeks of treatment (from baseline 14.1 +/- 1.5 to 25.4 +/- 1.8 p = 0.000). The third group (C) showed an improvement in all domains of IIEF questionnaire. Mean IIEF scores showed significant improvement after 8 weeks of treatment ( from baseline 6.7 +/- 1.4 to 13.9 +/- 2.0 p = 0.0000) [8] (TABLE 1) We report the mean baseline values of the 3 RigiScan items ( nocturnal erection number, rigidity of the penile percentile scale penile tumescence and duration of the nocturnal erections ) and the changes in RigiScan data before and after the treatment in the 150 evaluable patients [9] (TABLE 2) We also noted that the mean RigiScan parameters after 8 weeks of therapy revealed, in all three groups, significative increase in terms of number and duration of nocturnal erections and percentile scale tumescence of the penis. In fact Rigiscan test is improved in the 93.7% of the population, we found in particular, in Group A, a 17% increase an of the number of spontaneous erections and a 11% increase of the mean percentage of rigidity; In Group B an improvement equal to 39% of the number of erections and 6% of the rigidity. Also in the group C there were an amelioration regarding the number of the erections and penile rigidity equal to 75% and 38% respectively (TABLE 2) Testosterone levels improved in the group affected by mild ED (group A),from a mean baseline 5.3 +/- 1.1 ng/ml (normal range: 2.8 to 9.8 ng/ml [10]) to 6.8 +/- 1.6 (p<0.01)

post-treatment with an improvement of the 28%. Patients affected by moderate ED (group B) had an increase of the serum testosterone levels equal to 24%, from 5.0 +/- 1.1 ng/ml to 6.0 +/- 1.2 (p<0.01). Also in the group of patients with severe ED (group C) the testosterone values improved of the 24%, from 5.0 +/- 1.0 ng/ml to 6.2 +/- 1.3 (p<0.01) ng/ml (TABLE 3). Patient mean baseline serum level of total PSA was 1.8 +/- 0.6 ( normal range : 0 to 4 ng/ml ) in group A, 1.7 +/- 0.6 in group B and 1.8 +/- 0.7 in Group C. Moreover, there was no statistically significant difference regarding PSA in treated patients (TABLE 4). DISCUSSION In this study we attempted to evaluate the effectiveness of the combination of Tribulus Terrestris, Alga Ecklonia Bicyclis and Biovis contained in this new natural compound in the management of male sexual dysfunction. This new natural compound plays an important double role on cavernous tissue: therapeutical and antiaging, with an action on the etiopathogenetic aspects of ED, mainly the microstructural alteration of the corporus cavernosum tissues, following the inflammation-oxidative damage [11]. Tribulus Terrestris contains flavonoids, alkaloids and amides, although its properties seem to be comletely attribuited to protodioscin. The parts used are the seeds and fruits, and, more generally, the aerial parts of the plant. The protodioscin is a steroidal saponin, which is about 45% of the extract obtained from aerial parts of Tribulus terrestris. The substance due its chemical structure has an androgen-mimetic action binding and activating the testosterone receptors and is able to increase the endogenous production of testosterone, dihydrotestosterone, a hormone luteinizing hormone (LH)[12], dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEA-S)[13]. Because of these effects in experimental animals there is an increase in spermatogenesis and the frequency of the matches [14]. In the rabbit in particular has been shown that the compound stimulates the release of nitric oxide (NO) by vascular endothelium of the corpora cavernosa thereby having a pro-erectile effect [15;16]. The mechanism behind this effect appears to involve the pathway of steroid hormones. Although humans protodioscin is used for the treatment of erectile dysfunction. A study conducted on 406 Chinese patients with angina pectoris showed that protodioscin may be usefultreatment of this

cardiac pathology associated with coronary arteries dilation effect [17]. Dieckol, Florofucofuroeckol and Bieckol are phlorotannins, polyphenols contained in very high concentration in the Alga Ecklonia Bicyclis. Their scavenger activity is 10-100 powerful than any other polyphenol terrestris plants, including green tea catechins, which have only 3-4 fenolic rings that are commonly considered among the most effective antioxidant molecules. These properties are given by the fact that phlototannins are fat soluble at 40% so they have a longer half-life and action (12 hours) [18] compared to common polyphenols, soluble in water, with a relatively short half-life introduced into the body. In the Ecklonia bicyclis there are molecules that are able to reduce the response inflammatory, partially neutralizing the inflammatory damage caused by ROS and in part by slowing the gaming lipoxygenase and inhibiting the formation of prostaglandin E2, a powerful inflammatory mediator; furthermore it suppress proinflammatory cytokines like lipopolisaccarids, TNFalpha, IFN-gamma carrying out a potent antioxidant [19] and antifibrotic effect [20]. Biovis contains polymers of d-glucosamine and n-acetyl-d-glucosamine that act both on nonadrenergic and non-colinergic system (NANC) and on endothelial cell system as a strong nitric oxide synthetase (NOS) stimulator improving the concentration of nitric oxide (NO) in the smooth cells inside the corpus cavernosum [21]. CONCLUSIONS The most frequent requirement by men affected by ED is a product better natural than synthetic- that could work with a progressive action to improve their sexual function, with a curative and not just with a symptomatic action, also improving the sexual desire and with a possible anti-aging action. This product should not have any significant side effects and should be compatible with the assumption of other drugs. The use of PDE5 inhibitors is often linked with many side effects which negatively influence the entire sexual intercourse [2]. The use of a natural product, side effects free, that has got a real efficacy on the erection quality and on the sexual desire, could be the right way to cure and prevent the male sexual and erectile dysfunction. The compound used in our study, with Alga Ecklonia Bicyclis, Tribulus Terrestris and Biovis has proved a significant efficacy determining an improvement in both erection and

sexual desire in the majority of the patients we treated. Furthermore more clinical and histological researches are necessary to evaluate the efficacy of this new drug to inhibit degenerative changes with fibrosis and loss of smooth muscle in the corpora cavernosa in the ageing [22], in patients underwent to radical prostatectomy [23] and in patients affected by induratio penis plastica or La Peyronie disease [24]. REFERENCES 1.de Araujo AC, da Silva FG, Salvi F, Awad MC, da Silva EA, Damião R: The management of erectile dysfunction with placebo only: does it work? J Sex Med. 2009 Dec;6(12):3440-8. 2..Tsertsvadze A, Yazdi F, Fink HA, MacDonald R, Wilt TJ, Bella AJ, Ansari MT, Garritty C, Soares- Weiser K, Daniel K, Sampson M, and David Moher: Oral Sildenafil Citrate (Viagra) for Erectile Dysfunction: A Systematic Review and Meta-analysis of Harms. Urology, 74: 831-6, 2009 3.Dorsey P, Keel C, Klavens M, Hellstrom WJ: Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction. Expert Opin Pharmacother, 2010 May;11(7):1109-22. 4. Hachett G.: Hypertension medication and erectile dysfunction. Cardiovasc ther, 28 (1): 1-5, 2010 5. Ishii N, Kato T, Kataoka K, Ohira T, Takasugi K, Yamabe F, Deguchi M, Tanaka N, Nakajima K, Kurita M, Hara H, Nagao K, Miura K. : A study on sildenafil citrate non-responders at the ED clinic of reprduction center in the Toho University Omori Medical Center. Japanese Journal of Impotence Research. 2005, Vol 20, n.3 : 241-249 6. McKay D : Nutrients and botanicals for erectile dysfunction: examining the evidence. Altern Med Rev. 2004 Mar;9(1):4-16. 7.Iacono F., Prezioso D., Iapicca G., Taglialatela D., Ruffo A. Evaluating the efficacy in improving male sexual function with a new natural compound made of Tribulus Terrestris, Biovis and Alga Ecklonia and its synergic anti-aging action. 7 th Men s Health World Congress. Nice. October 28th to 30 th. 2010. Acts Book 8.Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH: Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology.1999,54:346-351. 9.Basar MM, Atan A, Tekdogan UY: New concept parameters of RigiScan in differentiation of vascular erectile dysfunction: is it a useful test? Int J Urol2001,8:686-91. 10. Wespes E, Amar E, Hatzichristou D, Hatzimouratidis K, Montorsi F, Pryor J, Vardi Y; EAU. EAU Guidelines on erectile dysfunction: an update. Eur Urol. 2006, 49:806-15.

11. Iacono F., Prezioso D., Iapicca G., Taglialatela D., Ruffo A. and Miclavez A.: Saponins, Phlorotannins and Glycosamine contained in Tribulus Terrestris, Biovis and Alga Ecklonia Cava in the treatment of Erectile Dysfunction : A Preliminary Study. Eur.Journ.Sexuology and Sexual Health. Vol.1 12. Koumanov F, Bozadjieva E, Andreeva M, Platonva E, Ankov V. Clinical trial of Tribestan. Experimental Medicine 1982;2-4. 13. Adimoelja A, Adaikan PG. Protodioscin from herbal plant Tribulus terrestris L. improves male sexual functions possibly via DHEA. International Journal of Impotence Research 1997;9(1):S64. 14. Tomova M, Gjulemetova R, Zarkova S, Peeva S, Pangarova T, Simova M. Steroidal saponins from Tribulus terrestris L. with a stimulating action on the sexual functions. International Conference of Chemistry and Biotechnology of Biologically Active Natural Products, Varna, Bulgaria, September 21 26, vol. 3. 1981. p. 298 302. 15. Gauthaman K, Adaikan PG, Prasad RN: Aphrodisiac properties of Tribulus terrestris extract (Protodioscin) in normal and castrated rats. Life Sci. 2002, 71:1385-96. 16. Gauthaman K, Ganesan AP: The hormonal effect of Tribulus terrestris and its role in the management of male erectile dysfunction: an evaluation using primates, rabbit and rat. Phytomedicine. 2008, 15:44-54. 17. Wang B, Ma L, Liu T. 406 cases of angina pectoris in coronary heart diseases treated with saponin of Tribulus terrestris. Chung His Chieh Ho Tsa Chih 1990;10(2):85 7. 18. Vandeklift MA, Wernberg T: Detached kelps from distant sources are a food subsidy for sea urchins. Oecologia. 2008, 157:327-35. 19. Shin HC, Hwang HJ, Kang KJ, Lee BH: An antioxidative and antiiflammatory agent for potential treatment of osteoarthritis from Ecklonia cava. Arch Pharm Res. 2006, 29:165-71. 20. Kang KA, Lee KH, Chae S, Zhang R, Jung MS, Lee Y, Kim SY, Kim HS, Joo HG, Park JW, Ham YM, Lee NH, Hyun JW: Eckol isolated from Ecklonia cava attenuates oxidative stress induced cell damage in lung fibroblast cells. FEBS Lett. 2005, 579:6295-304. 21. Kang et al : ''Proceeding of Current Biotechnology and Bioengineering (XIII) : October 22-24, 2003, COEX, Seoul, Korea, Proceeding P. 642 22. Kaiser FE : Erectile Dysfunction in the Aging Man. Med Clin North Am, 1999, n. 83, pag. 1267-1278. 23. Iacono F., Giannella R., Somma P., Manno G., Fusco F., Mirone V.: Histological Alterations In Cavernous Tissue After Radical Prostatectomy. J Urol, 2005, 173: 1673-1676. 24. Iacono F., Barra S., De Rosa G, Boscaino A., Lotti T.: Microstructural Disorders of Tunica Albuginea in Patients Affected by Peyronie s Desease with or without Erection Dysfunction. J Urol, 1993,150:1806-9